↓ Skip to main content

A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients…

Overview of attention for article published in Critical Care, February 2012
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
94 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock
Published in
Critical Care, February 2012
DOI 10.1186/cc11203
Pubmed ID
Authors

Peter E Morris, Brian Zeno, Andrew C Bernard, Xiangning Huang, Shampa Das, Timi Edeki, Steven G Simonson, Gordon R Bernard

Abstract

Tumor necrosis factor-alpha (TNF-α), an early mediator in the systemic inflammatory response to infection, is a potential therapeutic target in sepsis. The primary objective of this study was to determine the safety and tolerability of AZD9773, an ovine, polyclonal, anti-human TNF-α Fab preparation, in patients with severe sepsis. Secondary outcomes related to pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
France 1 1%
Singapore 1 1%
Brazil 1 1%
Unknown 90 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 18%
Other 14 15%
Researcher 14 15%
Student > Bachelor 11 12%
Student > Ph. D. Student 8 9%
Other 15 16%
Unknown 15 16%
Readers by discipline Count As %
Medicine and Dentistry 42 45%
Agricultural and Biological Sciences 7 7%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Nursing and Health Professions 4 4%
Biochemistry, Genetics and Molecular Biology 4 4%
Other 13 14%
Unknown 19 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2012.
All research outputs
#20,656,820
of 25,374,647 outputs
Outputs from Critical Care
#5,970
of 6,554 outputs
Outputs of similar age
#133,053
of 169,042 outputs
Outputs of similar age from Critical Care
#91
of 128 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,554 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.8. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,042 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 128 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.